Nuveen
TRDA icon

Nuveen’s Entrada Therapeutics TRDA Stock Holding History

Nuveen’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418K Sell
56,777
-118,871
-68% -$1.14M ﹤0.01% 3348
2026
Q1 		$2.22M Buy
175,648
+119,232
+211% +$1.37M ﹤0.01% 2240
2025
Q4 		$580K Hold
56,416
– – ﹤0.01% 2818
2025
Q3 		$327K Hold
56,416
– – ﹤0.01% 3033
2025
Q2 		$379K Sell
56,416
-10,600
-16% -$85.3K ﹤0.01% 2963
2025
Q1 		$606K Sell
67,016
-20,490
-23% -$255K ﹤0.01% 2839
2024
Q4 		$1.51M Sell
87,506
-42,360
-33% -$767K ﹤0.01% 2500
2024
Q3 		$2.08M Buy
129,866
+7,004
+6% +$110K ﹤0.01% 2393
2024
Q2 		$1.75M Buy
122,862
+65,725
+115% +$934K ﹤0.01% 2450
2024
Q1 		$810K Sell
57,137
-23,373
-29% -$330K ﹤0.01% 2780
2023
Q4 		$1.21M Buy
80,510
+7,148
+10% +$106K ﹤0.01% 2645
2023
Q3 		$1.16M Buy
73,362
+16,548
+29% +$261K ﹤0.01% 2519
2023
Q2 		$860K Buy
56,814
+43,827
+337% +$604K ﹤0.01% 2719
2023
Q1 		$188K Buy
+12,987
New +$173K ﹤0.01% 2998
2022
Q2 		– Sell
-13,872
Closed -$130K – 3477
2022
Q1 		$130K Hold
13,872
– – ﹤0.01% 3230
2021
Q4 		$237K Buy
+13,872
New +$336K ﹤0.01% 3217

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Nuveen's TRDA Position: Q2 2026 in Review

Nuveen reduced its Entrada Therapeutics (TRDA) stake by 68% in Q2 2026, selling an estimated $1.14M and leaving 56,777 shares worth $418K. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

Nuveen first reported a position in TRDA in Q4 2021 and has held it in 16 quarters since. The position peaked at $2.22M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Nuveen held 56,777 shares of Entrada Therapeutics worth $418K as of Q2 2026.
  • Nuveen sold 118,871 Entrada Therapeutics shares in Q2 2026, an estimated $1.14M.
  • Entrada Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3348 holding.
  • Nuveen first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Nuveen's Entrada Therapeutics position peaked at $2.22M in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.